||||||||||Blincyto (blinatumomab) / Astellas, Amgen Enrollment closed, Minimal residual disease: Phase II Study of the BiTE (clinicaltrials.gov) - Nov 19, 2012 P2, N=21, Active, not recruiting, Sponsor: Amgen Research (Munich) GmbH N=60 --> 76 Completed --> Active, not recruiting